Eli Lilly and Company
1,124.21USD
+0.2999 (+0.03%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 28.5B | 34.1B | 45.0B | 65.2B | 88.2B | 101.8B |
| Q1 | 7.8B | 7.0B | 8.8B | 12.7B | 19.8B | — |
| Q2 | 6.5B | 8.3B | 11.3B | 15.6B | 23.0B | — |
| Q3 | 6.9B | 9.5B | 11.4B | 17.6B | 22.2B | — |
| Q4 | 7.3B* | 9.4B* | 13.5B* | 19.3B* | 23.2B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 6.90 | 5.80 | 11.71 | 22.95 | 36.71 | 47.26 |
| Q1 | 2.10 | 1.49 | 2.48 | 3.06 | 8.26 | — |
| Q2 | 1.05 | 1.95 | 3.28 | 6.29 | 7.94 | — |
| Q3 | 1.61 | -.060 | 1.07 | 6.21 | 9.87 | — |
| Q4 | 2.14* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| 2.42* |
| 4.88* |
| 7.38* |
| 9.98 |
| — |